Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Photochemotherapy | 25 | 2020 | 97 | 2.950 |
Why?
|
Ultraviolet Therapy | 8 | 2018 | 15 | 1.490 |
Why?
|
Psoriasis | 16 | 2018 | 239 | 1.380 |
Why?
|
Aminolevulinic Acid | 14 | 2012 | 21 | 1.230 |
Why?
|
Photosensitizing Agents | 14 | 2020 | 48 | 1.130 |
Why?
|
Dermatologic Agents | 3 | 2018 | 71 | 1.060 |
Why?
|
Protoporphyrins | 8 | 2006 | 19 | 0.810 |
Why?
|
Methoxsalen | 12 | 2001 | 15 | 0.700 |
Why?
|
Ultraviolet Rays | 15 | 2015 | 193 | 0.610 |
Why?
|
PUVA Therapy | 15 | 1999 | 24 | 0.600 |
Why?
|
Biological Products | 1 | 2018 | 143 | 0.570 |
Why?
|
Photosensitivity Disorders | 8 | 1992 | 15 | 0.490 |
Why?
|
Skin Diseases | 3 | 2010 | 166 | 0.480 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2013 | 88 | 0.460 |
Why?
|
Skin Neoplasms | 11 | 2017 | 541 | 0.440 |
Why?
|
Keratinocytes | 4 | 2015 | 143 | 0.420 |
Why?
|
Immunoglobulin G | 2 | 2013 | 456 | 0.410 |
Why?
|
Porphyrins | 8 | 2012 | 39 | 0.400 |
Why?
|
Laser Therapy | 3 | 2017 | 142 | 0.330 |
Why?
|
Carcinoma, Basal Cell | 5 | 2017 | 54 | 0.330 |
Why?
|
Cell Differentiation | 4 | 2020 | 1456 | 0.300 |
Why?
|
Prostatic Neoplasms | 6 | 2006 | 1708 | 0.290 |
Why?
|
Lasers, Gas | 2 | 2017 | 4 | 0.280 |
Why?
|
Sebaceous Glands | 1 | 2006 | 28 | 0.280 |
Why?
|
Cryotherapy | 2 | 2017 | 29 | 0.280 |
Why?
|
Radiation-Sensitizing Agents | 4 | 2001 | 94 | 0.270 |
Why?
|
Deferoxamine | 4 | 1995 | 18 | 0.260 |
Why?
|
Vitiligo | 4 | 1988 | 15 | 0.240 |
Why?
|
Vitamin D | 3 | 2020 | 261 | 0.230 |
Why?
|
Humans | 63 | 2018 | 86281 | 0.210 |
Why?
|
Receptors, Immunologic | 2 | 2000 | 135 | 0.200 |
Why?
|
Tumor Cells, Cultured | 10 | 2002 | 1040 | 0.200 |
Why?
|
Skin | 11 | 1999 | 554 | 0.190 |
Why?
|
Khellin | 4 | 1988 | 4 | 0.190 |
Why?
|
Erythema | 5 | 1999 | 27 | 0.190 |
Why?
|
Hyperthermia, Induced | 1 | 2000 | 71 | 0.180 |
Why?
|
Neoplasms, Experimental | 1 | 2000 | 269 | 0.170 |
Why?
|
Keratosis, Actinic | 2 | 2015 | 11 | 0.160 |
Why?
|
Europe | 1 | 2018 | 308 | 0.160 |
Why?
|
Male | 28 | 2018 | 40860 | 0.160 |
Why?
|
Aged, 80 and over | 5 | 2018 | 6481 | 0.160 |
Why?
|
Neoadjuvant Therapy | 1 | 2020 | 315 | 0.160 |
Why?
|
Aged | 14 | 2018 | 18353 | 0.150 |
Why?
|
Dermatitis, Photoallergic | 2 | 1995 | 2 | 0.150 |
Why?
|
Lymphomatoid Granulomatosis | 2 | 1987 | 5 | 0.150 |
Why?
|
Physicians, Primary Care | 1 | 2018 | 104 | 0.150 |
Why?
|
Combined Modality Therapy | 6 | 2013 | 1680 | 0.150 |
Why?
|
Adolescent | 6 | 2018 | 8968 | 0.150 |
Why?
|
Disease Management | 1 | 2018 | 327 | 0.140 |
Why?
|
DNA-Binding Proteins | 1 | 2001 | 1208 | 0.130 |
Why?
|
Primary Health Care | 1 | 2018 | 339 | 0.130 |
Why?
|
Middle Aged | 15 | 2018 | 24957 | 0.130 |
Why?
|
Facial Dermatoses | 1 | 2014 | 13 | 0.120 |
Why?
|
Scalp Dermatoses | 1 | 2014 | 10 | 0.120 |
Why?
|
Young Adult | 2 | 2018 | 5961 | 0.120 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 1 | 1994 | 12 | 0.120 |
Why?
|
Baths | 4 | 1994 | 8 | 0.120 |
Why?
|
Transcription Factors | 1 | 2001 | 1555 | 0.120 |
Why?
|
Female | 21 | 2018 | 44405 | 0.120 |
Why?
|
Etanercept | 1 | 2013 | 32 | 0.120 |
Why?
|
Adult | 15 | 2018 | 25577 | 0.110 |
Why?
|
Gene Expression Regulation | 1 | 2001 | 1917 | 0.110 |
Why?
|
Severity of Illness Index | 1 | 2018 | 1796 | 0.110 |
Why?
|
Carcinoma, Squamous Cell | 5 | 2015 | 1075 | 0.110 |
Why?
|
Netherton Syndrome | 1 | 2012 | 2 | 0.110 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2013 | 137 | 0.110 |
Why?
|
Cutis Laxa | 1 | 1992 | 4 | 0.110 |
Why?
|
Methotrexate | 4 | 2012 | 249 | 0.110 |
Why?
|
Elastic Tissue | 1 | 1992 | 18 | 0.110 |
Why?
|
Drug Administration Schedule | 2 | 2013 | 916 | 0.110 |
Why?
|
Melanoma | 3 | 2013 | 454 | 0.110 |
Why?
|
Skin Aging | 1 | 1992 | 28 | 0.100 |
Why?
|
Phagocytosis | 1 | 1992 | 85 | 0.100 |
Why?
|
Cohort Studies | 1 | 2018 | 2759 | 0.100 |
Why?
|
Indoles | 1 | 2013 | 318 | 0.100 |
Why?
|
Matrix Metalloproteinase 9 | 2 | 2003 | 78 | 0.100 |
Why?
|
Prospective Studies | 3 | 2017 | 4194 | 0.100 |
Why?
|
Recurrence | 2 | 2013 | 1137 | 0.100 |
Why?
|
Sulfonamides | 1 | 2013 | 299 | 0.100 |
Why?
|
Superoxide Dismutase | 2 | 1999 | 177 | 0.100 |
Why?
|
Riboflavin | 1 | 1990 | 6 | 0.100 |
Why?
|
Neoplasms, Second Primary | 1 | 2013 | 252 | 0.100 |
Why?
|
Loose Anagen Hair Syndrome | 1 | 2010 | 5 | 0.100 |
Why?
|
Hair | 1 | 2010 | 56 | 0.090 |
Why?
|
Rats | 8 | 2003 | 3984 | 0.090 |
Why?
|
Ovarian Neoplasms | 3 | 2001 | 738 | 0.090 |
Why?
|
Animals | 19 | 2006 | 26518 | 0.090 |
Why?
|
Leiomyoma | 1 | 2013 | 189 | 0.090 |
Why?
|
Light | 4 | 2006 | 289 | 0.090 |
Why?
|
DNA | 4 | 1993 | 1293 | 0.090 |
Why?
|
Sulfadoxine | 1 | 1989 | 2 | 0.090 |
Why?
|
Sulfanilamides | 1 | 1989 | 5 | 0.090 |
Why?
|
Pyrimethamine | 1 | 1989 | 21 | 0.090 |
Why?
|
Chloroquine | 1 | 1989 | 12 | 0.090 |
Why?
|
Mice | 9 | 2006 | 11313 | 0.090 |
Why?
|
Lipid Peroxidation | 1 | 2009 | 44 | 0.090 |
Why?
|
Malaria | 1 | 1989 | 23 | 0.090 |
Why?
|
Stevens-Johnson Syndrome | 1 | 1989 | 22 | 0.090 |
Why?
|
Antimalarials | 1 | 1989 | 20 | 0.090 |
Why?
|
Cell Line | 2 | 2006 | 2466 | 0.080 |
Why?
|
Complement Activation | 1 | 2009 | 81 | 0.080 |
Why?
|
Niacinamide | 1 | 1988 | 116 | 0.080 |
Why?
|
Transcriptional Activation | 1 | 2009 | 280 | 0.080 |
Why?
|
Microscopy, Confocal | 2 | 2006 | 268 | 0.080 |
Why?
|
Metribolone | 2 | 2006 | 5 | 0.080 |
Why?
|
Macrophages | 4 | 2001 | 554 | 0.070 |
Why?
|
Treatment Outcome | 3 | 2014 | 7949 | 0.070 |
Why?
|
Eyelid Diseases | 1 | 1986 | 6 | 0.070 |
Why?
|
Microscopy, Fluorescence | 2 | 2006 | 424 | 0.070 |
Why?
|
Matrix Metalloproteinase Inhibitors | 2 | 2003 | 14 | 0.070 |
Why?
|
Dose-Response Relationship, Radiation | 7 | 2001 | 188 | 0.070 |
Why?
|
Mitochondria | 3 | 2006 | 535 | 0.070 |
Why?
|
RNA, Messenger | 3 | 2001 | 1975 | 0.070 |
Why?
|
Sunlight | 3 | 2015 | 26 | 0.070 |
Why?
|
Mice, Nude | 3 | 2001 | 790 | 0.070 |
Why?
|
Transcription, Genetic | 2 | 2001 | 1135 | 0.060 |
Why?
|
Apoptosis | 2 | 2009 | 1678 | 0.060 |
Why?
|
Cytokines | 1 | 2009 | 775 | 0.060 |
Why?
|
Fluorescent Dyes | 1 | 2006 | 242 | 0.060 |
Why?
|
Euglena gracilis | 2 | 1994 | 8 | 0.060 |
Why?
|
Chlorophyllides | 2 | 2001 | 5 | 0.060 |
Why?
|
Administration, Oral | 5 | 2002 | 683 | 0.060 |
Why?
|
Hydro-Lyases | 2 | 1994 | 6 | 0.060 |
Why?
|
Alcohol Oxidoreductases | 2 | 1994 | 17 | 0.060 |
Why?
|
Alkyl and Aryl Transferases | 2 | 1994 | 15 | 0.060 |
Why?
|
Lyases | 2 | 1994 | 11 | 0.060 |
Why?
|
Multienzyme Complexes | 2 | 1994 | 64 | 0.060 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 2 | 1994 | 80 | 0.060 |
Why?
|
Piperazines | 2 | 2003 | 272 | 0.060 |
Why?
|
Testosterone Congeners | 1 | 2002 | 2 | 0.060 |
Why?
|
Pyrimidines | 2 | 2003 | 370 | 0.050 |
Why?
|
Cell Division | 4 | 2002 | 696 | 0.050 |
Why?
|
Enzyme Inhibitors | 2 | 2003 | 632 | 0.050 |
Why?
|
Tretinoin | 1 | 2002 | 125 | 0.050 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2002 | 27 | 0.050 |
Why?
|
beta-Galactosidase | 1 | 2001 | 71 | 0.050 |
Why?
|
Cells, Cultured | 4 | 2001 | 2810 | 0.050 |
Why?
|
Mice, Inbred Strains | 1 | 2001 | 305 | 0.050 |
Why?
|
Deuteroporphyrins | 1 | 2001 | 1 | 0.050 |
Why?
|
Organotin Compounds | 1 | 2001 | 1 | 0.050 |
Why?
|
Mutagenesis, Insertional | 1 | 2001 | 111 | 0.050 |
Why?
|
Receptors, Scavenger | 1 | 2000 | 3 | 0.050 |
Why?
|
Scavenger Receptors, Class A | 1 | 2000 | 5 | 0.050 |
Why?
|
Cell Survival | 3 | 2006 | 966 | 0.050 |
Why?
|
Biopsy | 3 | 1992 | 1160 | 0.050 |
Why?
|
Flow Cytometry | 1 | 2002 | 679 | 0.050 |
Why?
|
Serum Albumin, Bovine | 1 | 2000 | 45 | 0.050 |
Why?
|
DNA Primers | 1 | 2001 | 542 | 0.050 |
Why?
|
Forkhead Transcription Factors | 1 | 2001 | 166 | 0.050 |
Why?
|
Phenylalanine | 1 | 2000 | 37 | 0.050 |
Why?
|
Hematoporphyrin Derivative | 2 | 1996 | 3 | 0.050 |
Why?
|
Thiophenes | 1 | 2000 | 48 | 0.050 |
Why?
|
Antibodies, Antinuclear | 2 | 1992 | 83 | 0.050 |
Why?
|
Drug Carriers | 1 | 2000 | 81 | 0.050 |
Why?
|
DNA Replication | 2 | 1993 | 164 | 0.050 |
Why?
|
Follow-Up Studies | 6 | 1996 | 3616 | 0.040 |
Why?
|
Integrin beta1 | 1 | 1999 | 33 | 0.040 |
Why?
|
Impetigo | 1 | 1999 | 1 | 0.040 |
Why?
|
Bowen's Disease | 2 | 1996 | 9 | 0.040 |
Why?
|
Neoplasms | 2 | 2012 | 2889 | 0.040 |
Why?
|
Dermatitis Herpetiformis | 1 | 1999 | 9 | 0.040 |
Why?
|
Polyethylene Glycols | 1 | 2001 | 363 | 0.040 |
Why?
|
Extracellular Matrix Proteins | 1 | 1999 | 123 | 0.040 |
Why?
|
Time Factors | 5 | 2002 | 5198 | 0.040 |
Why?
|
Porphobilinogen Synthase | 1 | 1998 | 4 | 0.040 |
Why?
|
Heme | 1 | 1998 | 62 | 0.040 |
Why?
|
Phototherapy | 1 | 2018 | 35 | 0.040 |
Why?
|
Promoter Regions, Genetic | 1 | 2001 | 937 | 0.040 |
Why?
|
Temperature | 1 | 1999 | 395 | 0.040 |
Why?
|
Signal Transduction | 1 | 2009 | 3233 | 0.040 |
Why?
|
Biological Therapy | 1 | 2018 | 45 | 0.040 |
Why?
|
Transferases | 2 | 1994 | 24 | 0.040 |
Why?
|
Hordeum | 1 | 1997 | 10 | 0.040 |
Why?
|
Plant Growth Regulators | 1 | 1997 | 10 | 0.040 |
Why?
|
Mice, Transgenic | 1 | 2001 | 1537 | 0.040 |
Why?
|
Cyclopentanes | 1 | 1997 | 27 | 0.040 |
Why?
|
Torso | 1 | 2017 | 12 | 0.040 |
Why?
|
Gene Expression Regulation, Plant | 1 | 1997 | 91 | 0.040 |
Why?
|
Radiotherapy Dosage | 2 | 1999 | 468 | 0.040 |
Why?
|
Genes, Plant | 2 | 1997 | 99 | 0.040 |
Why?
|
Administration, Cutaneous | 2 | 1993 | 58 | 0.040 |
Why?
|
Skin Pigmentation | 2 | 1988 | 40 | 0.040 |
Why?
|
Photochemistry | 2 | 2001 | 38 | 0.040 |
Why?
|
Dermatology | 1 | 1996 | 35 | 0.040 |
Why?
|
Extremities | 1 | 2017 | 165 | 0.040 |
Why?
|
Pemphigoid, Bullous | 1 | 1996 | 12 | 0.030 |
Why?
|
Sunscreening Agents | 1 | 2015 | 7 | 0.030 |
Why?
|
Paraneoplastic Syndromes | 1 | 1995 | 16 | 0.030 |
Why?
|
Sunburn | 1 | 2015 | 8 | 0.030 |
Why?
|
Neoplasm Transplantation | 3 | 2002 | 391 | 0.030 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 1995 | 28 | 0.030 |
Why?
|
Pyoderma Gangrenosum | 1 | 1995 | 19 | 0.030 |
Why?
|
Patch Tests | 1 | 1995 | 4 | 0.030 |
Why?
|
Survival Rate | 2 | 2002 | 1856 | 0.030 |
Why?
|
Biomarkers, Tumor | 1 | 2003 | 1461 | 0.030 |
Why?
|
Child | 4 | 1996 | 6913 | 0.030 |
Why?
|
Erythrocytes | 3 | 1990 | 255 | 0.030 |
Why?
|
Receptors, Cell Surface | 2 | 1986 | 286 | 0.030 |
Why?
|
Deoxyribodipyrimidine Photo-Lyase | 1 | 1993 | 1 | 0.030 |
Why?
|
Pyrimidine Dimers | 1 | 1993 | 4 | 0.030 |
Why?
|
Fibroblasts | 2 | 1994 | 729 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2002 | 1958 | 0.030 |
Why?
|
Dermatitis, Phototoxic | 1 | 1993 | 2 | 0.030 |
Why?
|
Calcium | 1 | 1998 | 1148 | 0.030 |
Why?
|
Oxygen Consumption | 2 | 2006 | 239 | 0.030 |
Why?
|
Tumor Stem Cell Assay | 1 | 1993 | 35 | 0.030 |
Why?
|
Phosphotransferases | 1 | 1993 | 65 | 0.030 |
Why?
|
Thymidine | 1 | 1993 | 59 | 0.030 |
Why?
|
Metabolic Clearance Rate | 1 | 1993 | 121 | 0.030 |
Why?
|
Darkness | 1 | 1993 | 49 | 0.030 |
Why?
|
Glycine | 1 | 1993 | 90 | 0.030 |
Why?
|
Gene Amplification | 1 | 1993 | 131 | 0.030 |
Why?
|
Methylprednisolone | 2 | 1995 | 66 | 0.030 |
Why?
|
Skin Tests | 2 | 1993 | 44 | 0.030 |
Why?
|
Oxygen | 2 | 2012 | 725 | 0.030 |
Why?
|
Plant Proteins | 1 | 1993 | 131 | 0.030 |
Why?
|
Drug Resistance | 1 | 1993 | 256 | 0.030 |
Why?
|
Amino Acid Substitution | 1 | 2013 | 339 | 0.030 |
Why?
|
Antibodies, Monoclonal | 1 | 2018 | 1376 | 0.030 |
Why?
|
Mutation, Missense | 1 | 2013 | 276 | 0.030 |
Why?
|
Child, Preschool | 2 | 2010 | 3608 | 0.030 |
Why?
|
DNA Repair | 1 | 1993 | 356 | 0.020 |
Why?
|
Physical Examination | 1 | 1992 | 149 | 0.020 |
Why?
|
Incidence | 1 | 2015 | 1568 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2014 | 452 | 0.020 |
Why?
|
Differential Threshold | 1 | 1990 | 12 | 0.020 |
Why?
|
Superoxides | 1 | 1990 | 73 | 0.020 |
Why?
|
Cell Line, Tumor | 2 | 2006 | 2421 | 0.020 |
Why?
|
Rejuvenation | 1 | 2010 | 18 | 0.020 |
Why?
|
Radiation-Protective Agents | 1 | 1990 | 96 | 0.020 |
Why?
|
Microscopy | 1 | 2010 | 87 | 0.020 |
Why?
|
Radiation Injuries | 2 | 1989 | 155 | 0.020 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 1992 | 206 | 0.020 |
Why?
|
Organometallic Compounds | 1 | 1990 | 132 | 0.020 |
Why?
|
Gangliosides | 2 | 1986 | 10 | 0.020 |
Why?
|
Amiodarone | 1 | 1989 | 12 | 0.020 |
Why?
|
Pigmentation Disorders | 1 | 1989 | 13 | 0.020 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 1995 | 755 | 0.020 |
Why?
|
In Vitro Techniques | 1 | 1990 | 987 | 0.020 |
Why?
|
Up-Regulation | 2 | 2006 | 710 | 0.020 |
Why?
|
Antineoplastic Agents | 1 | 2000 | 2351 | 0.020 |
Why?
|
Lymphocytes | 1 | 1990 | 461 | 0.020 |
Why?
|
Clinical Trials as Topic | 3 | 1988 | 1168 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 1994 | 1932 | 0.020 |
Why?
|
Drug Combinations | 1 | 1989 | 222 | 0.020 |
Why?
|
Facial Neoplasms | 1 | 1987 | 25 | 0.020 |
Why?
|
Necrosis | 1 | 1987 | 204 | 0.020 |
Why?
|
Rats, Inbred Strains | 2 | 2003 | 312 | 0.020 |
Why?
|
Coproporphyrinogen Oxidase | 1 | 2006 | 1 | 0.020 |
Why?
|
Cyclophosphamide | 1 | 1987 | 299 | 0.020 |
Why?
|
Tetrazolium Salts | 1 | 2006 | 11 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 1989 | 893 | 0.020 |
Why?
|
Pyrimidinones | 1 | 2006 | 36 | 0.020 |
Why?
|
Trioxsalen | 1 | 1986 | 2 | 0.020 |
Why?
|
Eyelids | 1 | 1986 | 23 | 0.020 |
Why?
|
Alanine Transaminase | 1 | 1986 | 73 | 0.020 |
Why?
|
Aspartate Aminotransferases | 1 | 1986 | 73 | 0.020 |
Why?
|
Thiazoles | 1 | 2006 | 131 | 0.020 |
Why?
|
Melanocytes | 1 | 1986 | 56 | 0.020 |
Why?
|
Chemical and Drug Induced Liver Injury | 1 | 1986 | 68 | 0.020 |
Why?
|
Seasons | 1 | 1986 | 223 | 0.020 |
Why?
|
Amino Acids | 2 | 1997 | 252 | 0.020 |
Why?
|
3-Phosphoshikimate 1-Carboxyvinyltransferase | 2 | 1994 | 2 | 0.020 |
Why?
|
Lymphoma | 1 | 1986 | 262 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 1988 | 1752 | 0.020 |
Why?
|
Chloroplasts | 2 | 1994 | 68 | 0.020 |
Why?
|
Liver Diseases | 1 | 1986 | 238 | 0.010 |
Why?
|
Phenotype | 1 | 2010 | 2375 | 0.010 |
Why?
|
Neoplasm Metastasis | 1 | 1987 | 1056 | 0.010 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2003 | 44 | 0.010 |
Why?
|
Matrix Metalloproteinases | 1 | 2002 | 28 | 0.010 |
Why?
|
Papanicolaou Test | 1 | 2002 | 38 | 0.010 |
Why?
|
Vaginal Smears | 1 | 2002 | 68 | 0.010 |
Why?
|
Polylysine | 1 | 2001 | 33 | 0.010 |
Why?
|
Subcellular Fractions | 1 | 2001 | 93 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2006 | 1571 | 0.010 |
Why?
|
Pregnancy | 2 | 1999 | 2885 | 0.010 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2001 | 458 | 0.010 |
Why?
|
Ventilation | 1 | 1999 | 7 | 0.010 |
Why?
|
Skin Temperature | 1 | 1999 | 14 | 0.010 |
Why?
|
Sodium Azide | 1 | 1999 | 5 | 0.010 |
Why?
|
Deuterium Oxide | 1 | 1999 | 10 | 0.010 |
Why?
|
Catalase | 1 | 1999 | 48 | 0.010 |
Why?
|
Hematoporphyrins | 1 | 1999 | 1 | 0.010 |
Why?
|
Models, Biological | 1 | 2006 | 1748 | 0.010 |
Why?
|
Molecular Sequence Data | 2 | 1994 | 3029 | 0.010 |
Why?
|
Arsenic | 2 | 1996 | 251 | 0.010 |
Why?
|
Lysosomes | 1 | 1999 | 104 | 0.010 |
Why?
|
Disease Progression | 1 | 2003 | 1531 | 0.010 |
Why?
|
Spectrometry, Mass, Secondary Ion | 1 | 1997 | 2 | 0.010 |
Why?
|
Pregnancy Complications, Infectious | 1 | 1999 | 105 | 0.010 |
Why?
|
Cell Adhesion | 1 | 1999 | 418 | 0.010 |
Why?
|
Oxylipins | 1 | 1997 | 16 | 0.010 |
Why?
|
Gas Chromatography-Mass Spectrometry | 1 | 1997 | 40 | 0.010 |
Why?
|
Stereoisomerism | 1 | 1997 | 102 | 0.010 |
Why?
|
Plant Leaves | 1 | 1997 | 72 | 0.010 |
Why?
|
Dihematoporphyrin Ether | 1 | 1996 | 4 | 0.010 |
Why?
|
Membrane Proteins | 1 | 1984 | 1194 | 0.010 |
Why?
|
Metalloporphyrins | 1 | 1996 | 26 | 0.010 |
Why?
|
Sarcoma, Kaposi | 1 | 1996 | 19 | 0.010 |
Why?
|
Molecular Structure | 1 | 1997 | 287 | 0.010 |
Why?
|
Administration, Topical | 1 | 1996 | 94 | 0.010 |
Why?
|
Structure-Activity Relationship | 1 | 1997 | 408 | 0.010 |
Why?
|
Biomarkers | 1 | 2003 | 1709 | 0.010 |
Why?
|
Tars | 1 | 1996 | 1 | 0.010 |
Why?
|
Fluorescent Antibody Technique, Direct | 1 | 1996 | 10 | 0.010 |
Why?
|
Cocarcinogenesis | 1 | 1996 | 12 | 0.010 |
Why?
|
Retinoids | 1 | 1996 | 17 | 0.010 |
Why?
|
Fluorescent Antibody Technique, Indirect | 1 | 1996 | 68 | 0.010 |
Why?
|
Complement C3 | 1 | 1996 | 58 | 0.010 |
Why?
|
Chronic Disease | 1 | 1999 | 968 | 0.010 |
Why?
|
Dapsone | 1 | 1995 | 10 | 0.010 |
Why?
|
X-Rays | 1 | 1996 | 130 | 0.010 |
Why?
|
Rosette Formation | 2 | 1986 | 34 | 0.010 |
Why?
|
Keratosis | 1 | 1995 | 21 | 0.010 |
Why?
|
Basement Membrane | 1 | 1996 | 54 | 0.010 |
Why?
|
Immunoglobulin M | 1 | 1996 | 154 | 0.010 |
Why?
|
Pregnancy Trimester, Second | 1 | 1995 | 66 | 0.010 |
Why?
|
Epidermis | 1 | 1996 | 100 | 0.010 |
Why?
|
Switzerland | 1 | 1995 | 17 | 0.010 |
Why?
|
Austria | 1 | 1995 | 19 | 0.010 |
Why?
|
Immunoblotting | 1 | 1996 | 267 | 0.010 |
Why?
|
Germany | 1 | 1995 | 72 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2002 | 2227 | 0.010 |
Why?
|
RNA, Plant | 1 | 1994 | 20 | 0.010 |
Why?
|
Radiation Dosage | 1 | 1996 | 227 | 0.010 |
Why?
|
Ferrochelatase | 1 | 1994 | 1 | 0.010 |
Why?
|
Cyclosporine | 1 | 1995 | 234 | 0.010 |
Why?
|
Autoantibodies | 1 | 1996 | 267 | 0.010 |
Why?
|
Cytosol | 1 | 1994 | 189 | 0.010 |
Why?
|
Verapamil | 1 | 1994 | 48 | 0.010 |
Why?
|
Skin Transplantation | 1 | 1995 | 172 | 0.010 |
Why?
|
Spectrometry, Fluorescence | 1 | 1994 | 85 | 0.010 |
Why?
|
Regression Analysis | 1 | 1996 | 595 | 0.010 |
Why?
|
Allergens | 1 | 1995 | 179 | 0.010 |
Why?
|
Biological Transport | 1 | 1994 | 396 | 0.010 |
Why?
|
Opossums | 1 | 1993 | 4 | 0.010 |
Why?
|
Oligonucleotide Probes | 1 | 1993 | 39 | 0.010 |
Why?
|
Enzyme Induction | 1 | 1993 | 88 | 0.010 |
Why?
|
Risk Factors | 2 | 1996 | 5397 | 0.010 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 1993 | 268 | 0.010 |
Why?
|
Carcinoma, Transitional Cell | 1 | 1994 | 164 | 0.010 |
Why?
|
Species Specificity | 1 | 1993 | 678 | 0.010 |
Why?
|
DNA Damage | 1 | 1993 | 362 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 1994 | 2062 | 0.010 |
Why?
|
Adaptation, Physiological | 1 | 1993 | 306 | 0.010 |
Why?
|
Urinary Bladder Neoplasms | 1 | 1994 | 376 | 0.010 |
Why?
|
Base Sequence | 1 | 1993 | 2329 | 0.010 |
Why?
|
Microscopy, Electron | 1 | 1989 | 502 | 0.010 |
Why?
|
Face | 1 | 1989 | 114 | 0.010 |
Why?
|
Furocoumarins | 1 | 1988 | 2 | 0.010 |
Why?
|
Chemistry | 1 | 1988 | 54 | 0.010 |
Why?
|
Chemical Phenomena | 1 | 1988 | 72 | 0.010 |
Why?
|
Mesocricetus | 1 | 1988 | 107 | 0.010 |
Why?
|
Yeasts | 1 | 1988 | 49 | 0.010 |
Why?
|
Cross-Linking Reagents | 1 | 1988 | 86 | 0.010 |
Why?
|
Biological Availability | 1 | 1988 | 92 | 0.000 |
Why?
|
Diagnosis, Differential | 1 | 1992 | 1562 | 0.000 |
Why?
|
Random Allocation | 1 | 1988 | 332 | 0.000 |
Why?
|
Genes | 1 | 1988 | 305 | 0.000 |
Why?
|
Cricetinae | 1 | 1988 | 560 | 0.000 |
Why?
|
Etretinate | 1 | 1986 | 4 | 0.000 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 1986 | 42 | 0.000 |
Why?
|
Binding, Competitive | 1 | 1986 | 145 | 0.000 |
Why?
|
Carbohydrates | 1 | 1986 | 46 | 0.000 |
Why?
|
Sialic Acids | 1 | 1984 | 18 | 0.000 |
Why?
|
Neuraminic Acids | 1 | 1984 | 10 | 0.000 |
Why?
|
Cycloheximide | 1 | 1984 | 56 | 0.000 |
Why?
|
Trypsin | 1 | 1984 | 95 | 0.000 |
Why?
|
Lactose | 1 | 1984 | 27 | 0.000 |
Why?
|
Breast Neoplasms | 1 | 1996 | 2881 | 0.000 |
Why?
|
Retrospective Studies | 1 | 1996 | 8431 | 0.000 |
Why?
|
Mutation | 1 | 1993 | 3952 | 0.000 |
Why?
|
Aging | 1 | 1986 | 689 | 0.000 |
Why?
|
Neoplasm Recurrence, Local | 1 | 1986 | 1305 | 0.000 |
Why?
|
T-Lymphocytes | 1 | 1986 | 1195 | 0.000 |
Why?
|